Literature DB >> 33254031

Reverse genetics for influenza B viruses and recent advances in vaccine development.

Stivalis Cardenas-Garcia1, C Joaquin Caceres2, Daniela Rajao2, Daniel R Perez3.   

Abstract

Influenza B virus is a respiratory pathogen that affects more severely the pediatric and elderly populations. There are two lineages of influenza B virus that seem to have differential predilection for age groups. Both lineages can co-circulate during the influenza season however one is usually more prominent than the other depending on the season. There are no defined indicators to predict which lineage will dominate in any given season. In recent years, the addition of viruses from both lineages to the seasonal influenza vaccine formulation has improved vaccine protection, although quadrivalent vaccines are not available worldwide. Reverse genetics has facilitated advancements in the field of vaccine development against influenza B virus. Different strategies have been explored showing promising results that could potentially lead to the development broadly protective influenza B virus vaccines.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33254031      PMCID: PMC8693393          DOI: 10.1016/j.coviro.2020.10.005

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  80 in total

1.  The NB protein of influenza B virus is not necessary for virus replication in vitro.

Authors:  Masato Hatta; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  Transmission of influenza B viruses in the guinea pig.

Authors:  Natalie Pica; Yi-Ying Chou; Nicole M Bouvier; Peter Palese
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  Comparative epidemiology of influenza B by lineage in intensive care unit-admitted patients with complications: A nationwide study in Taiwan, 2013-2017.

Authors:  Hsueh-Ju Chen; Chia-Ping Su; Ming-Tsan Liu; Tsung-Pei Tsou
Journal:  Int J Infect Dis       Date:  2019-07-26       Impact factor: 3.623

4.  Pilot studies on recombinant cold-adapted live type A and B influenza virus vaccines.

Authors:  F M Davenport; A V Hennessy; H F Maassab; E Minuse; L C Clark; G D Abrams; J R Mitchell
Journal:  J Infect Dis       Date:  1977-07       Impact factor: 5.226

5.  The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses.

Authors:  Natalie Pica; Arun Iyer; Irene Ramos; Nicole M Bouvier; Ana Fernandez-Sesma; Adolfo García-Sastre; Anice C Lowen; Peter Palese; John Steel
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

6.  Generation of influenza A viruses entirely from cloned cDNAs.

Authors:  G Neumann; T Watanabe; H Ito; S Watanabe; H Goto; P Gao; M Hughes; D R Perez; R Donis; E Hoffmann; G Hobom; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

7.  Domestic pigs are susceptible to infection with influenza B viruses.

Authors:  Zhiguang Ran; Huigang Shen; Yuekun Lang; Elizabeth A Kolb; Nuri Turan; Laihua Zhu; Jingjiao Ma; Bhupinder Bawa; Qinfang Liu; Haixia Liu; Megan Quast; Gabriel Sexton; Florian Krammer; Ben M Hause; Jane Christopher-Hennings; Eric A Nelson; Juergen Richt; Feng Li; Wenjun Ma
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

8.  Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.

Authors:  Nina Wressnigg; Daniel Voss; Thorsten Wolff; Julia Romanova; Tanja Ruthsatz; Ines Mayerhofer; Manfred Reiter; Sabine Nakowitsch; Johannes Humer; Alexander Morokutti; Thomas Muster; Andrej Egorov; Christian Kittel
Journal:  Vaccine       Date:  2009-03-11       Impact factor: 3.641

9.  The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century.

Authors:  Saverio Caini; Gabriela Kusznierz; Verònica Vera Garate; Sonam Wangchuk; Binay Thapa; Francisco José de Paula Júnior; Walquiria Aparecida Ferreira de Almeida; Richard Njouom; Rodrigo A Fasce; Patricia Bustos; Luzhao Feng; Zhibin Peng; Jenny Lara Araya; Alfredo Bruno; Doménica de Mora; Mónica Jeannette Barahona de Gámez; Richard Pebody; Maria Zambon; Rocio Higueros; Rudevelinda Rivera; Herman Kosasih; Maria Rita Castrucci; Antonino Bella; Hervé A Kadjo; Coulibaly Daouda; Ainash Makusheva; Olga Bessonova; Sandra S Chaves; Gideon O Emukule; Jean-Michel Heraud; Norosoa H Razanajatovo; Amal Barakat; Fatima El Falaki; Adam Meijer; Gé A Donker; Q Sue Huang; Tim Wood; Angel Balmaseda; Rakhee Palekar; Brechla Moreno Arévalo; Ana Paula Rodrigues; Raquel Guiomar; Vernon Jian Ming Lee; Li Wei Ang; Cheryl Cohen; Florette Treurnicht; Alla Mironenko; Olha Holubka; Joseph Bresee; Lynnette Brammer; Mai T Q Le; Phuong V M Hoang; Clotilde El Guerche-Séblain; John Paget
Journal:  PLoS One       Date:  2019-09-12       Impact factor: 3.240

10.  NB protein does not affect influenza B virus replication in vitro and is not required for replication in or transmission between ferrets.

Authors:  Ruth A Elderfield; Marios Koutsakos; Rebecca Frise; Konrad Bradley; Jonathan Ashcroft; Shanhjahan Miah; Angie Lackenby; Wendy S Barclay
Journal:  J Gen Virol       Date:  2015-12-24       Impact factor: 3.891

View more
  2 in total

1.  Influenza NP core and HA or M2e shell double-layered protein nanoparticles induce broad protection against divergent influenza A viruses.

Authors:  Yao Ma; Ye Wang; Chunhong Dong; Gilbert X Gonzalez; Yufeng Song; Wandi Zhu; Joo Kim; Lai Wei; Bao-Zhong Wang
Journal:  Nanomedicine       Date:  2021-11-04       Impact factor: 5.307

2.  A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines.

Authors:  Chantelle L White; Kevin Chiem; Daniel R Perez; Jefferson Santos; Stivalis Cardenas Garcia; Aitor Nogales; Luis Martínez-Sobrido
Journal:  Viruses       Date:  2021-06-30       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.